If it is determined that rhLCAT, synthetic APOC-I, or other drugs to increase LCAT activity can also improve bone metabolism, their clinical applications will be much broader, and they could be prescribed to regulate lipid metabolism to improve obesity and obesity-induced cardiovascular disease, metabolic syndrome, and even diabetes, as well as to prevent related bone complications (61). The gene discussed is APOC1; the disease is Obesity.